RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2

Pirsch, 1997, Transplantation, 63, 977, 10.1097/00007890-199704150-00013

Mayer, 1997, Transplantation, 64, 436, 10.1097/00007890-199708150-00012

1996, Transplantation, 61, 1029, 10.1097/00007890-199604150-00008

1995, Lancet, 1, 1321

Sollinger, 1995, Transplantation, 60, 225, 10.1097/00007890-199508000-00003

Mendez, 1998, Transplant Proc, 30, 1287, 10.1016/S0041-1345(98)00244-9

Vanrenterghem, 1998, Transplant Proc, 30, 1290, 10.1016/S0041-1345(98)00245-0

Ochiai, 1991, Transplant Proc, 23, 2718

Murase, 1993, Transplantation, 55, 701, 10.1097/00007890-199304000-00003

Tanabe, 1994, Transplantation, 58, 23, 10.1097/00007890-199407000-00005

Shapiro, 1998, J Urol, 160, 1982, 10.1016/S0022-5347(01)62219-5

Yang, 1999, Transplant Proc, 31, 1121, 10.1016/S0041-1345(98)01929-0

Shapiro, 1999, Transplantation, 67, 411, 10.1097/00007890-199902150-00012

Shah, 1999, Transplantation, 11, 1411, 10.1097/00007890-199906150-00004

Pelletier, 1998, Clin Transplant Evidence that severity is the best predictor of subsequent graft survival time, 12, 543

Hansen, 1997, J Am Soc Nephrol, 8, 684a, 10.1681/ASN.V84684

Neylan, 1998, Am J Kid Dis, 32, 770, 10.1016/S0272-6386(98)70132-5